# Botulinum Toxin for Trigeminal Neuralgia

> **NCT03331913** · PHASE3 · UNKNOWN · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 150 (estimated)

## Conditions studied

- Trigeminal Neuralgia

## Interventions

- **DRUG:** Botulinum Toxin type A (intradermal / submucosal injection at pain area)
- **DRUG:** Botulinum Toxin type A (intra-masseter injection on the ipsilateral of pain involved)

## Key facts

- **NCT ID:** NCT03331913
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-07
- **Primary completion:** 2019-02-28
- **Final completion:** 2019-03-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2018-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03331913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03331913, "Botulinum Toxin for Trigeminal Neuralgia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03331913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*